The therapeutic effect of entecavir combined with HBsAg nanoemulsion for chronic hepatitis B

Liu Jianxiang

doi:10.3969/j.issn.1672-8521.2017.01.013

Abstract：Objective:To observe the clinical effect ofentecavir combined with HBsAg nanoemulsion in treatment of patients with chronic hepatitis B.Methods:Sixty patients with chronic hepatitis B admitted in the 163rd Hospital of PLA during Sep.2015 to Apr.2016 were randomly assigned into two groups (30 each):based on liver protection treatment,patients in combination group were treated with entecavir combining HBsAg nanoemulsion,and those in control group were treated with entecavir only.The negative rate of HBV DNA and HBeAg,and the levels of alanine aminotransferase (ALT) and total bilirubin (TBIL) were compared between the two groups.Results:The HBV DNA level significantly decreased in combination group than in control group 3 and 6 months after treatment (P＜0.05).The negative conversion rates of serum virus and the HBeAg in combination group (90.00％ and 26.67％) were significantly higher than that in control group (46.67％ and 3.33％) 6 months after treatment (P＜0.01).The liver function (levels of ALT and TBIL) in combination group was significantly lower 3 and 6 months after treatment than that before treatment (P＜0.05) and that in control group (P＜0.05).But the liver function was aggravated in one case of combination group.Conclusions:Entecavir combined with HBsAg nanoemulsion in treatment of chronic hepatitis B may effectively increase the negative conversion rates of serum virus and HBeAg,and improve the liver function compared to that in control group,but the safety of HBsAg nanoemulsion should be closely noticed.